ARTHR-IS (Arthroplasties’ infections due to Staphylococcus aureus) aims to characterize the frequency of prosthetic joint infections due to Staphylococcus aureus, and using a case-control methodology, to identify the risk factors for these infections and the predictors of treatment failure.
Thanks to the teamwork of the different partners: Hospital Universitario Virgen Macarena (Seville), UMCU (Utrecht) and GSK Vaccine (Siena), the selection process of centers was finished in March 2019.
In the process, 76 centers were contacted, 47 completed the feasibility questionnaire and 20 were finally selected. The included hospitals are 3 in France (Hôpital de la Croix Rousse, CHU de Rennes and Hôpital Ambroise Paré), 2 in Italy (Policlinico Sant’Orsola-Malpighi and IRCCS Istituto Clinico Humanitas), 4 centers in the Netherlands (Sint Maartenskliniek, OLVG, Máxima Medisch Centrum and Amphia Hospital), 2 hospitals in Germany (Universitätsklinikum Jena and Universitätsklinikum Frankfurt), 6 in Spain (Hospital del Mar, Hospital Universitario 12 de Octubre, Hospital Universitario Ramón y Cajal, Hospital Universitario Virgen Macarena, Hospital de la Santa Creu and Sant Pau and Hospital Universitari de Bellvitge) and 3 in the United Kingdom (Sheffield Teaching Hospitals, North Manchester General Hospital and St Thomas).
Data collection has already begun at the Hospital Universitario Virgen Macarena, where 8 cases and 24 controls have been included. The project management team is actively working with local investigators in order to get the contracts and IRBs approvals in the selected hospitals.
The ARTHR-IS team would like to send their sincere appreciation to all the centers that participated in the selection process, and to those selected for their acceptance and effort to carry out this project.